Pesquisas alternativas:
"esto open" » "tests open" (Expandir a Pesquisa), "esto en" (Expandir a Pesquisa), "nest open" (Expandir a Pesquisa)
"eso open" » "caso open" (Expandir a Pesquisa), "two open" (Expandir a Pesquisa), "do open" (Expandir a Pesquisa), "edo open" (Expandir a Pesquisa), "eao open" (Expandir a Pesquisa), "eo open" (Expandir a Pesquisa)
"oto open" » "two open" (Expandir a Pesquisa)
"so open" » "do open" (Expandir a Pesquisa), "ao open" (Expandir a Pesquisa), "o open" (Expandir a Pesquisa)
"esmo open" » "ecmo open" (Expandir a Pesquisa)
A mostrar 1 - 20 resultados de 1,117 para a pesquisa '(((("eso open") OR ((("esmo open") OR ((("esto open") OR ("oto open"))))))) OR ("so open"))*', tempo de pesquisa: 2.82seg Refinar resultados
Presenting OTO Open
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

ESMO Open—Cancer Horizons and the future of oncology
CSCO joins ESMO Open—Cancer Horizons

ESMO Open: news in breast cancer 2019
ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

ESMO Open special series on new emerging targets in cancer immunotherapy
Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

One year of ESMO Open: Cancer Horizons—where are we going from here?
Plasmodesmata. A Not So Open-and-Shut Case

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]
Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa